Venus Remedies gets patent for anti-ICU infection drug

The GLP-accredited research centre of Venus Remedies Limited, headquartered at Panchkula in Haryana, Venus Medicine Research Center has received another patent grant for a novel antibiotic product, VRP008, consisting of a carbapenem and a novel amino glycoside (NCE entity) from EPO. This product is the outcome of eight years of research by Venus Medicine Research Centre, pioneering into antimicrobial resistance research.

"We, at VMRC, have been working dedicatedly to provide effective and affordable solution to the compounding problem of anti-microbial resistance ever since we recognised this problem more than 10 years ago. The sincerity and hard work of our team is reflected in the patents received from all over the globe for our novel antibiotic entities such as Elores, Potentox, Vancoplus and VRP008. Once launched, VRP008 will be one of the best solutions for ICU infections," said Manu Chaudhary, Joint Managing Director of Venus Remedies.